EZH2 and acute myeloid leukemia: The histone methyltransferase enhancer of zeste homolog 2 (EZH2) is a target of MYB and both factors were downregulated by the EZH2 inhibitor EPZ011989 in AML cells via proteasomal degradation, which was accompanied by apoptosis induction and G2/M arrest.